Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa
Abstract
SUMMARYPseudomonas aeruginosa is a frequent cause of hospital-acquired infections and is notable both for its virulence and its resistance to multiple antibiotics. In the absence of head-to-head clinical trials and availability of all potential options on a global basis, we have systematically analyzed potential antibiotics for carbapenem-resistant P. aeruginosa. Monotherapy with ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol, or high doses of ceftolozane-tazobactam is generally considered an acceptable option for serious infections due to carbapenem-resistant P. aeruginosa. The role of testing combinations of antimicrobial agents for in vitro susceptibility is uncertain, as is the administration of nebulized colistin or amikacin in patients with ventilator-associated pneumonia. With regard to new therapies, 10 clinical trials are underway or have been completed on bacteriophage therapy for P. aeruginosa infections. However, no phage options are yet widely approved for use. Other new options in clinical trials include beta-lactam antibiotics combined with new beta-lactamase inhibitors and antibody-based therapies.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.